Serious fungal infections cause 1.3 million deaths annually worldwide.
Researchers have identified a new class of antifungals to treat the more than 300 million people worldwide who develop serious fungal infections
The research is described in the current issue of mBio, the online open-access journal of the American Society for Microbiology.
“Fungal infections are a significant cause of morbidity and mortality worldwide and current antifungal drugs have drawbacks. These new drugs may pave the way for the development of a new class of antifungals,” said principal investigator Maurizio Del Poeta, MD, a professor in the Department of Molecular Genetics and Microbiology at Stony Brook University, Stony Brook, New York.
Fungal infections are most commonly found in individuals with medical conditions that compromise the immune system, such as AIDS, or individuals who are being treated with immunosuppressives, such as those battling cancer. The three classes of antifungal drugs currently available—azoles, polyenes, and echinocandins—are far from optimal.
“Even with treatment, the mortality rate of invasive fungal infections is over 50%,” said Dr. Del Poeta. “The drugs don’t work that well. They are toxic, so they affect other organs, and they are static, meaning they may be able to stop a fungus from replicating but they are not able to kill the fungus.” Current antifungals also have a narrow spectrum of activity, and some interact with other drugs such as chemotherapy agents and immunosuppressants.”
Previous research has shown that when fungal cells lack a lipid called glucosylceramide (GlcCer), they are unable to replicate. Seeking to exploit this weakness and develop a new class of antifungals, an international group of researchers screened a synthetic drug library for compounds that target the synthesis of fungal but not mammalian GlcCer. “The enzymes that are important for the synthesis of fungal glucosylceramide are different than the ones important for the synthesis of mammalian glucosylceramide,” said Dr. Del Poeta. “We thought that because the pathway is totally different, we could specifically target the fungal glucosylceramide without affecting mammalian glucosylceramide, and that is exactly what we did.”
They identified two compounds, BHBM and its derivative DO, that decreased levels of fungal but not mammalian glucosylceramide. In test tube and animal studies, these compounds were highly effective against several pathogenic fungi and were well tolerated in animals. The drugs were effective when used alone or in combination with other classes of antifungals. The researchers plan to spend the next five years fine-tuning their research and identifying even more effective compounds that inhibit fungal glucosylceramide.
Serious fungal infections cause 1.3 million deaths annually worldwide. The most common and life-threatening fungal infections are cryptococcosis, candidiasis, aspergillosis, and pneumocystosis.
The Latest on: Antifungals
via Google News
The Latest on: Antifungals
- Combination Antifungal Therapy for Invasive Fungal Infections in Children and Adultson October 7, 2020 at 5:01 pm
Second, there is a greater chance of drug interactions. Azole antifungals (e.g., fluconazole, itraconazole and voriconazole) alter metabolism of cyclophosphamide, a cytotoxic agent, through ...
- Global Antifungal Drug Market Is Set for a Rapid Growth and is Expected to Reach Approximately USD 14.10 Billion by 2021on October 7, 2020 at 9:21 am
Compromised immune system and torpid lifestyle to power the global antifungal drug market in the forecast period The antifungal drug market is mainly boosted by rising prevalence of fungal infection ...
- How long does nicotine stay in your system? A few days to a few months, depending on how frequently you smokeon October 7, 2020 at 8:13 am
How long nicotine stays in your system depends on what type of nicotine test you're taking and how frequently you smoke.
- Combination Antifungal Therapy for Invasive Fungal Infections in Children and Adultson October 4, 2020 at 5:00 pm
 Nikkomycin Z, a chitin synthase inhibitor, has been evaluated with various combinations of other antifungals and demonstrated synergy with caspofungin and micafungin.  A very recent ...
- Namubiru’s journey of battling leukemiaon October 3, 2020 at 9:13 am
After spending six months in hospital and undergoing rounds of chemotherapy, blood transfusion, antibiotics, antivirals, antifungals and steroids, Annet Victoria Namubiru has a reason to smile.
- New potential broad-spectrum fungicides discoveredon September 23, 2020 at 8:30 am
"Widespread antifungal use imposes selection pressures on fungal pathogens, allowing accumulation of mutations promoting resistance against antifungals," said study leader Xuewei Chen, director of the ...
- Fungal infections: The not-so-hidden health crisis threatening millionson September 8, 2020 at 2:50 pm
Although there are more than 20 different classes of antibiotics (with different action mechanisms) that may be used to treat bacterial infections, antifungals all belong to one of three classes ...
- Tinea Pedis Treatment Market Research Report Projection By Technology, Type, Sale, Revenue, Demand Report 2020-2025on August 27, 2020 at 9:42 am
Based on drug class it covers Antifungals and Steroids and Anti-Infective Combinations. Based on route of administration it covers topical and Oral. The TineaPedis Treatment Market on geographic ...
- APO-Fluconazole Oneon August 15, 2020 at 5:03 am
Fluconazole belongs to a group of medicines known as azole antifungals. Vaginal thrush is an infection caused by a yeast-like fungus called Candida. Candida is one of the many organisms that live ...
- 10 Best Antifungalson September 24, 2019 at 7:43 pm
Please give an overall site rating: ...
via Bing News